Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma Post date 28 May 2024 ← Mailed feedback to primary care physicians on antibiotic prescribing → Covid-19: South African disclosures reveal secretive world of nations’ vaccine contracts